Accumulation Factor
Accumulation Factor - Related Videos
01:27
Cost Accumulation and Flow
0 Views •
2026
In manufacturing, production costs are accumulated and tracked to understand how resources are consumed and how they contribute to the final product. This process, known as cost accumulation, involves recording material, labor, and overhead costs and linking them to specific cost objects, such as individual products or production processes.Costs flow through inventory accounts in a sequence that mirrors the physical movement of goods. Initially, raw materials are recorded in the raw materials...
04:02
An Assay to Measure the Accumulation of a Fluorescent Antibiotic Probe in Bacterial Cells
0 Views •
2025
This video demonstrates an assay to measure the accumulation of a fluorescent antibiotic probe in bacterial cells. Exposure to an efflux pump inhibitor disrupts the transmembrane proton gradient in bacterial cells, upon which a fluorophore-conjugated antibiotic is added. Inhibition of efflux pumps due to the disrupted proton gradient causes accumulation of the antibiotic inside the bacteria. Bacterial cells are lysed, and the fluorescence intensity is measured to confirm antibiotic accumulation.
09:48
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
0 Views •
Cited by 1 •
2024
Here, we describe the protocol for in vivo delivery of magnetic iron oxide nanoparticles carrying RNA oligomers to metastatic breast cancer in animal models, providing a clinically viable approach for the therapeutic silencing of oncogenic nucleic acids.
02:16
Transcription Factors
0 Views •
2019
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
09:00
Spatial Measurements of Perfusion, Interstitial Fluid Pressure and Liposomes Accumulation in Solid Tumors
0 Views •
Cited by 6 •
2016
The heterogeneous intra-tumoral accumulation of liposomes has been linked to an abnormal tumor microenvironment. Herein methods are presented to measure tumor microcirculation by perfusion imaging and elevated interstitial fluid pressure (IFP) using an image-guided robotic system. Measurements are compared to the intra-tumoral accumulation of liposomes, determined using volumetric micro-CT imaging.
FAQs
The key driver is the relationship between elimination half-life and dosing interval. When the interval is short relative to the time required to eliminate the drug, more of the preceding dose remains when the next dose arrives, increasing subsequent concentrations. A longer interval allows more elimination and therefore produces less accumulation.
The increase becomes progressively smaller as repeated doses approach steady state. Early doses contribute both new drug and residual drug from prior doses, but the residual contribution eventually balances the amount eliminated between doses. This pattern helps clinicians anticipate that measured concentrations may change during treatment before settling into a stable exposure range.
Half-life and dosing interval should be considered together, not separately. A drug with a longer half-life retains more of each dose over a given interval, whereas extending the interval permits greater elimination before the next dose. Consequently, the same dosing interval can produce different accumulation factors for drugs with different half-lives.
To use the measure clinically, compare exposure during repeated dosing with exposure after a single dose, then interpret the result in light of the planned interval and the drug’s half-life. This approach connects the numerical factor to the dosing schedule and indicates whether repeated administration is likely to produce substantially higher concentrations or exposure.
Accumulation factor helps interpret both trough and peak concentrations during therapy. Residual drug raises later concentrations, so the lowest concentration before a dose and the highest concentration after dosing may differ from values observed after an isolated dose. Reviewing these patterns supports selection or evaluation of a dose interval intended to achieve stable exposure.
Clinical concern increases when accumulation raises concentrations or exposure beyond the intended range. By relating the factor to half-life and dosing interval, clinicians can anticipate how much exposure may build and how long treatment may take to approach stable levels. That information supports assessment of potential toxicity during repeated dosing.